Logo
Menu
  • Who We Are
  • How We Invest
  • Our Portfolio
    • Abzena
    • Ixlayer
    • Kiniciti
    • Labviva
    • PathAI
  • Blog
  • Careers
  • Contact
Moneyball for Private Equity

Moneyball for Private Equity

by Biospring | Apr 26, 2022 | Analytics, Decision Making, Investing, Moneyball, Portfolio Management, Returns

Drew Pearson, Biospring’s Chief Operating Officer, recently led a discussion for Limited Partners on best practices in Portfolio Management. We’re pleased to share a recap of the discussion below. “When I think about private equity as an industry,...
Kiniciti, Ncardia, and the Future of Cell & Gene Therapy

Kiniciti, Ncardia, and the Future of Cell & Gene Therapy

by Biospring | Apr 26, 2022 | Advanced Therapy, Cell Therapy, CGT, Gene Therapy, Geoffrey Glass, IPSC, Kiniciti, NCardia

In November 2021, we were pleased to announce our investment in Kiniciti, a Cell & Gene Therapy (“CGT”) aggregator. Later in November, Kiniciti announced its first strategic partnership with Ncardia, a leader in developing stem cell-based solutions for...
Our investment in Kiniciti

Our investment in Kiniciti

by Biospring | Apr 26, 2022 | Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Kiniciti

We’re pleased to announce our investment in Kiniciti, a Cell and Gene Therapy (“CGT”) aggregator. We’ve had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market. Biospring’s...
The Opportunities for AI in Drug Discovery

The Opportunities for AI in Drug Discovery

by Biospring | Apr 26, 2022 | Artificial Intelligence, Data, Drug Discovery, Health Care, John Baldoni, Pharma

We recently hosted a discussion with Dr. John Baldoni, one of Biospring’s Operational Experts. He is the Co-Founder and Chief Scientific Officer of SaponiQx, a recently formed vaccine discovery and development company. He’s also the CEO of the Atom...
How ixlayer is driving telehealth transformation

How ixlayer is driving telehealth transformation

by Biospring | Apr 26, 2022 | Health Care, Ixlayer, Labs, Precision Health, Telehealth

We are excited to be investors in ixlayer, a company that’s reinventing the health ecosystem by empowering every individual to manage their health testing at home. ixlayer’s technology infrastructure and software is leveraged by large enterprises to enable...
« Older Entries
Next Entries »

Recent Posts

  • Biospring Partners Welcomes Industry Executives To Its Advisory Board
  • Biomanufacturing: A Growing Field
  • Interview with Zach Weinberg
  • Driving Drug Development with Data Science
  • Proteomics 101

Recent Comments

No comments to show.

Newsletter

Thank you for subscribing!

Subscribe